Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | GALR3 | O60755 | 3/20 | 0.60 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | AGER | Q15109 | 1/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31498004 | 1.00 | TNF (0.64) | TNFLMNASMN1; SMN2ALDH1A1GALR3 | |
| SCHEMBL1520226 | 0.85 | KMT2A (0.62) | TNFLMNASMN1; SMN2ALDH1A1GALR3 | |
| SCHEMBL6446137 | 0.84 | LMNA (0.69) | TNFLMNASMN1; SMN2ALDH1A1GALR3 | |
| SCHEMBL1104819 | 0.82 | TNF (0.66) | TNFLMNASMN1; SMN2ALDH1A1GALR3 | |
| SCHEMBL10389744 | 0.81 | LMNA (0.62) | TNFLMNASMN1; SMN2ALDH1A1GALR3 | |
| Hydrochloric Acid SCHEMBL8009001 | 0.81 | PKM (0.64) | TNFLMNASMN1; SMN2ALDH1A1GALR3 | |
| SCHEMBL11130492 | 0.81 | TNF (0.64) | TNFLMNASMN1; SMN2ALDH1A1GALR3 | |
| SCHEMBL4728183 | 0.81 | TNF (0.64) | TNFLMNASMN1; SMN2ALDH1A1GALR3 | |
| SCHEMBL9260111 | 0.80 | TNF (0.77) | TNFLMNASMN1; SMN2ALDH1A1GALR3 | |
| SCHEMBL2330274 | 0.79 | LMNA (0.69) | TNFLMNASMN1; SMN2ALDH1A1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-0276942-B1 | 6-BETA(SUBSTITUTED)-(S)-HYDROXYMETHYLPENICILLANIC ACIDS AND DERIVATIVES THEREOF | PFIZER INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| US-4782050-A | BACTERICIDES | PFIZER INC. (US) | 1988-11-01 | — | — | US | disclosed |
| EP-0276942-A1 | 6-Beta(substituted)-(S)-hydroxymethylpenicillanic acids and derivatives thereof | PFIZER INC. (US) | 1988-08-03 | — | — | EP | disclosed |
| EP-0195947-A2 | Beta-lactam antibiotics, process for their preparation and their use as and in medicaments | BAYER AG (DE) | 1986-10-01 | — | — | EP | disclosed |
| US-3929705-A | Preservatives for surface-coating compositions | KAY-FRIES HOLDING INC. | 1975-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | TNF 3789/4885LMNA 2469/4885SMN1; SMN2 478/4885 |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | TNF 1/4885LMNA 435/4885SMN1; SMN2 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.